Table of Contents Table of Contents
Previous Page  78 / 812 Next Page
Information
Show Menu
Previous Page 78 / 812 Next Page
Page Background

S74

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S72–S115

Anxiety disorders and somatoform disorders

FC05

Searching for new markers of panic

disorder – the examination of stem

cells mobilization and levels of factors

involved in their trafficking

Jolanta Kucharska-Mazur

1 ,

, Marcin Jabło ´nski

1

,

Maciej Tarnowski

2

, Barbara Doł˛egowska

3

, Z. Ratajczak Mariusz

4

,

Jerzy Samochowiec

1

1

Department of Psychiatry, Pomeranian University of Medicine,

Szczecin, Poland

2

Department of Physiology, Pomeranian University of Medicine,

Szczecin, Poland

3

Department of Medical Analytics, Pomeranian University of

Medicine, Szczecin, Poland

4

Stem Cell Biology Program at the James Graham Brown Cancer

Center, University of Louisville, Louisville, KY 40202, USA

Corresponding author.

Introduction

Regeneration processes are the new target in look-

ing for biological markers of psychiatric disorders.

Aims

In this study, we considered the role of stem cells and fac-

tors responsible for their trafficking in panic disorder (PD).

Methods

A group of 30 patients with panic disorder was

examined and compared with a group of 30 healthy vol-

unteers. In peripheral blood we have analysed: the number

of hematopoetic stem cells – HSC (Lin

/CD45+/CD34+) and

HSC (Lin

/CD45+/AC133+), the number of very small embry-

onic – like stem cells – VSEL (Lin

/CD45

/CD34+) and VSEL

(Lin

/CD45

/CD133+) and concentration of stromal derived

factor-1 (SDF-1), sphingosine-1-phosphate (S1P), and some pro-

teins of the complement cascade.

Results

Peripheral

blood concentration of

HSCs

(Lin

/CD45+/AC133+) was significantly lower in PD group com-

pared to control group, before and after antidepressant treatment.

Peripheral blood concentration of VSEL (Lin

/CD45

/CD133+)

was significantly lower in PD group before treatment compared

to concentration after treatment. In PD group concentrations of

factors involved in stem cell trafficking were statistically signifi-

cant lower in PD group (before and after treatment) compared to

control group.

Conclusion

Examination of regeneration system seems to be use-

ful in PD diagnostics.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

Acknowledgments

This work was supported by grant

POIG.01.01.02-00-109/09.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.009

Bipolar disorders

FC06

Multimorbidity in affective disorders:

Impact on length of stay

F. Cealicu Toma

, J. Moamaï

University of Ottawa, Psychiatry, Gatineau, Canada

Corresponding author.

Background

Multimorbidity (MM) refers to the coexistence of

two or more chronic diseases in the same individual; it encom-

passes medical comorbidity (MC) and psychiatric comorbidity (PC).

Hypothesis: MM is prevalent amongst in-patients suffering from

affective disorders (AD) and also impacted on length of stay.

Aims

To determine the prevalence of MMand its impact on dura-

tion of hospitalization in AD admissions.

Method

This cross-sectional study was conducted using sec-

ondary data taken from discharge records of 1056 adults admitted

for AD to a Quebec-based facility, between 2006 and 2014. Distri-

bution of AD cases: 47% depression, 53% bipolar disorders.

Results

The prevalence rate of MM: 85%. PC was present in 70%

of sample whereas MC was present in 62%. The median number

of comorbid illnesses was 2.7 for each study subject. The rate of

MM was not related to age or gender. Metabolic syndrome (54%),

cardiovascular diseases and chronic pain syndrome (17%) were the

most prevalent MC in both depressed and bipolar populations. Per-

sonality disorder (65%) was highest in the depression population,

whereas substance misuse (55%) was the most prevalent PC in the

bipolar subjects. A longer length of stay was correlated with MM.

However, a logistic regression analysis indicated that duration of

hospitalization was only correlated with MC.

Conclusions

The observation that MM is the norm, even in this

relatively young populationwith AD. The results confirmed thatMC

prolongs hospital stay. These findings advocate strongly for inte-

grated management of psychiatric and physical health problems in

clinical practice.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.010

FC07

Trends of hospitalization for bipolar I

in USA: A nationwide analysis

Z. Mansuri

1 ,

, U. Mansuri

2

, M. Rathod

3

, S. Shambhu

1

, K. Karnik

4

1

Drexel University, School of Public Health, Philadelphia, USA

2

Icahn School of Medicine at Mount Sinai, School of Public Health,

New York, USA

3

Drexel School of Public Health, School of Public Health, Philadelphia,

USA

4

Children’s Hospital of San Antonio - Texas, Department of

Pediatrics, San Antonio, USA

Corresponding author.

Objectives

Bipolar I (B-I) is an important cause of morbidity and

mortality in hospitalized patients. While B-I has been extensively

studied in the past, the contemporary data for impact of B-I on cost

of hospitalization are largely lacking.

Methods

We queried the Healthcare Cost and Utilization

Project’s Nationwide Inpatient Sample (HCUP-NIS) dataset

between 1998–2011 using the ICD-9 codes. Severity of comorbid

conditions was defined by Deyo modification of Charlson comor-

bidity index. Primary outcome was in-hospital mortality and

secondary outcome was total charges for hospitalization. Using

SAS 9.2, Chi

2

test,

t

-test and Cochran-Armitage test were used to

test significance.

Results

A total of 1,80,681 were analyzed; 56.29% were female

and 43.71% were male (

P

< 0.0001); 70.63% were white, 17.14%

black and 12.23% of other race (

P

< 0.0001). Rate of hospital-

ization increased from 7469.65/million to 9375.27/million from

1998–2011. Overall mortality was 0.12% and mean cost of hos-

pitalization was 19,821.50$. The in-hospital mortality increased

from 0.13% to 0.16% (

P

< 0.0001) and mean cost of hospitalization

increased from 12,091.31$ to 29,292.97$. Total yearly spending on

B-I related admissions increased from $0.72 million/year to $2.16

billion/year.

Conclusions

While mortality has slightly increased from 1998 to

2011, the cost has significantly increased from $0.72 million/year

to $2.16 billion/year, which leads to an estimated $1.46 billion/year

additional burden to US health care system. In the era of cost

conscious care, preventing B-I related Hospitalization could save